Quick Answer
Taysha Gene Therapies, Inc. reported Shares Outstanding of 285.05 million shares for fiscal year 2025.
Taysha Gene Therapies, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 285.05M | +39.1% |
| 2024 | 204.94M | +9.6% |
| 2023 | 186.96M | +195.8% |
| 2022 | 63.21M | +64.3% |
| 2021 | 38.47M | +1.9% |
| 2020 | 37.76M | +246.6% |
| 2019 | 10.89M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 273.92M | +33.7% | +0.4% |
| June 30, 2025 | 272.73M | +35.4% | +33.0% |
| March 31, 2025 | 205.05M | +9.6% | +0.1% |
| December 31, 2024 | 204.94M | +9.6% | +0.0% |
| September 30, 2024 | 204.94M | +9.6% | +1.8% |
| June 30, 2024 | 201.38M | +212.5% | +7.7% |
| March 31, 2024 | 187.02M | +194.6% | +0.0% |
| December 31, 2023 | 186.96M | +195.8% | +0.0% |
- Taysha Gene Therapies, Inc. showed an increase of +39.1% in Shares Outstanding compared to the prior fiscal year.
- Over the 2019–2025 period, Taysha Gene Therapies, Inc.’s shares outstanding has grown by 2516.4% (from 10.89 million shares to 285.05 million shares).
- The most recent figure is from Taysha Gene Therapies, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: